Ratnapradipa Kendra L, Yellala Amulya, Shonka Nicole
Department of Epidemiology, University of Nebraska Medical Center, 984395 Nebraska Medical Center, Omaha, Nebraska, USA.
Department of Internal Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Neurooncol Pract. 2023 Aug 25;11(1):64-68. doi: 10.1093/nop/npad050. eCollection 2024 Feb.
Central nervous system (CNS) cancers including gliomas have low incidence but high mortality. The age-adjusted incidence rate for CNS cancers is higher in Nebraska than nationally. This exploratory study was motivated by glioma patient inquiries about possible clustering of cases within the state to see if more in-depth investigation was warranted.
Using electronic health records from Nebraska Medicine, we identified Nebraska adult (age ≥19) glioma patients diagnosed between January 1, 2009 and November 1, 2019. Patient residential addresses were geocoded, mapped, and combined with annual US Census data to compute age-adjusted incidence rates (AAIR) at the county level. Counties with fewer than five cases were excluded to protect patient identity. ArcGIS software was used for geocoding and mapping.
Of the 285 cases included in the analysis, 53.2% were geocoded with exact match and the remainder were processed manually. Cases occurred in 47 of the 93 counties. After data suppression, 11 counties (228 cases) visually clustered in eastern and central Nebraska with AAIR ranging from 0.85 to 5.66 per 100 000.
Many counties in the state were excluded from analysis of this rare cancer due to the small number of cases leading to unstable rates and the need to suppress data to protect patient privacy. However, this preliminary study suggests that glioma incidence is highest in central and eastern Nebraska. Next steps include analysis of state cancer registry data to ensure more complete case ascertainment.
包括胶质瘤在内的中枢神经系统(CNS)癌症发病率低但死亡率高。内布拉斯加州中枢神经系统癌症的年龄调整发病率高于全国水平。这项探索性研究的起因是胶质瘤患者询问该州病例是否可能存在聚集现象,以确定是否有必要进行更深入的调查。
利用内布拉斯加医学中心的电子健康记录,我们确定了2009年1月1日至2019年11月1日期间被诊断为胶质瘤的内布拉斯加州成年(年龄≥19岁)患者。对患者的居住地址进行地理编码、绘图,并与美国年度人口普查数据相结合,以计算县级年龄调整发病率(AAIR)。病例数少于5例的县被排除,以保护患者身份。使用ArcGIS软件进行地理编码和绘图。
分析纳入的285例病例中,53.2%的病例地理编码完全匹配,其余病例进行人工处理。93个县中有47个县出现了病例。数据抑制后,11个县(228例)在视觉上聚集在内布拉斯加州东部和中部,年龄调整发病率为每10万人0.85至5.66例。
由于病例数少导致发病率不稳定,且需要抑制数据以保护患者隐私,该州许多县被排除在这种罕见癌症的分析之外。然而,这项初步研究表明,内布拉斯加州中部和东部的胶质瘤发病率最高。下一步包括分析州癌症登记数据,以确保更全面地确定病例。